These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 34327344)

  • 1. Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study.
    Mu R; Li C; Li X; Ke Y; Zhao L; Chen L; Wu R; Wu Z; Zuo X; Xie Y; Chen J; Wei W; Liu Y; Li Z; Dai L; Sun L; Liu X; Li Z
    Lancet Reg Health West Pac; 2021 May; 10():100128. PubMed ID: 34327344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Ouyang D; Ma YZ; Zou J; Wang YL; Chen Z; Yang YY; Zou B; Li X; Cao JZ
    Front Pharmacol; 2022; 13():911810. PubMed ID: 35991879
    [No Abstract]   [Full Text] [Related]  

  • 3. The SMILE study: Study of long-term methotrexate and iguratimod combination therapy in early rheumatoid arthritis.
    Du F; Dai Q; Teng J; Lu L; Ye S; Ye P; Lin Z; Ding H; Dai M; Bao C;
    Chin Med J (Engl); 2024 Jul; ():. PubMed ID: 39056160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Effect and Safety of Iguratimod Combined With Methotrexate on Rheumatoid Arthritis: A Systematic Review and Meta-Analysis Based on a Randomized Controlled Trial.
    Zeng L; Yu G; Yang K; Hao W; Chen H
    Front Pharmacol; 2021; 12():780154. PubMed ID: 35115930
    [No Abstract]   [Full Text] [Related]  

  • 5. Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs.
    Hu CJ; Zhang L; Zhou S; Jiang N; Zhao JL; Wang Q; Tian XP; Zeng XF
    J Orthop Surg Res; 2021 Jul; 16(1):457. PubMed ID: 34271950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-invasive vagus nerve stimulation for rheumatoid arthritis: a proof-of-concept study.
    Marsal S; Corominas H; de Agustín JJ; Pérez-García C; López-Lasanta M; Borrell H; Reina D; Sanmartí R; Narváez J; Franco-Jarava C; Peterfy C; Narváez JA; Sharma V; Alataris K; Genovese MC; Baker MC
    Lancet Rheumatol; 2021 Apr; 3(4):e262-e269. PubMed ID: 38279410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study).
    Kennedy WP; Simon JA; Offutt C; Horn P; Herman A; Townsend MJ; Tang MT; Grogan JL; Hsieh F; Davis JC
    Arthritis Res Ther; 2014 Oct; 16(5):467. PubMed ID: 25359150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effectiveness and Retention Rate of Iguratimod in Japanese Rheumatoid Arthritis Patients with/without Methotrexate in Daily Medical Care.
    Inoue A; Nozaki Y; Hirooka Y; Kinoshita K; Chiba Y; Funauchi M; Matsumura I
    Life (Basel); 2020 Oct; 10(11):. PubMed ID: 33138014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The efficacy and safety of tocilizumab combined with disease-modifying anti-rheumatoid drugs in the treatment of active rheumatoid arthritis: a multi-center, randomized, double-blinded, placebo-controlled trial].
    Shi Q; Zhao Y; Bao CD; Li XF; Huang F; Zhu P; Li ZG; Gu JR; Zhang ZY; Zhao DB; Zhao SL; Jiang QD; Tian J; Zhang FC
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):323-9. PubMed ID: 23925361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Adalimumab plus methotrexate for the treatment of rheumatoid arthritis: a multi-center randomized, double-blind, placebo-controlled clinical study.].
    Huang F; Zhang FC; Bao CD; Tao Y; Gu JR; Xu JH; Zhu P; Xu HJ; Zhang ZY; Zhao DB; Wu DH
    Zhonghua Nei Ke Za Zhi; 2009 Nov; 48(11):916-21. PubMed ID: 20079321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens.
    Zintzaras E; Dahabreh IJ; Giannouli S; Voulgarelis M; Moutsopoulos HM
    Clin Ther; 2008 Nov; 30(11):1939-55. PubMed ID: 19108784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.
    Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Ikeuchi S; Kushimoto S; Koike T
    Mod Rheumatol; 2017 Sep; 27(5):755-765. PubMed ID: 27919207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of etanercept in patients with moderately active rheumatoid arthritis despite DMARD therapy.
    Hobbs K; Deodhar A; Wang B; Bitman B; Nussbaum J; Chung J; Collier DH
    Springerplus; 2015; 4():113. PubMed ID: 25793152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
    Mizutani S; Kodera H; Sato Y; Nanki T; Yoshida S; Yasuoka H
    Clin Rheumatol; 2021 Jan; 40(1):123-132. PubMed ID: 32506311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of iguratimod in the treatment of rheumatic and autoimmune diseases: a meta-analysis and systematic review of 84 randomized controlled trials.
    Zeng L; He Q; Deng Y; Li Y; Chen J; Yang K; Luo Y; Ge A; Zhu X; Long Z; Sun L
    Front Pharmacol; 2023; 14():1189142. PubMed ID: 38143490
    [No Abstract]   [Full Text] [Related]  

  • 17. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness and safety of 99Tc-methylene diphosphonate as a disease-modifying anti-rheumatic drug (DMARD) in combination with conventional synthetic (cs) DMARDs in the treatment of rheumatoid arthritis: A systematic review and meta-analysis of 34 randomized controlled trials.
    Deng G; Chen X; Shao L; Wu Q; Wang S
    Heliyon; 2023 Nov; 9(11):e21691. PubMed ID: 37942155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.
    Li Z; Zhang F; Kay J; Fei K; Han C; Zhuang Y; Wu Z; Hsia EC
    Int J Rheum Dis; 2016 Nov; 19(11):1143-1156. PubMed ID: 26259617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.